ceftazidime/NXL104 + metronidazole
DrugIV TID
NCT Number: NCT00752219
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
UMHAT Sveti Georgi 3rd Clinical of Surgery, Plovdiv, Bulgaria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
IV TID
IV TID
Other names: merrem
Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline.
Time frame: Baseline up to 6 weeks after last dose of study treatment (up to a maximum of 8 weeks)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state.
Time frame: End of IV therapy: From Day 5 to Day 14
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.
Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.
Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)
Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.
Time frame: End of IV therapy: From Day 5 to Day 14
Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.
Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)
Favorable: eradication (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication (absence of material to culture in a patient who had responded clinically to treatment)
Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.
Time frame: End of IV therapy: From Day 5 to Day 14
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.
Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)
Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.
Pfizer
Industry
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01072539
Community-acquired Bacterial Pneumonia, Complicated Intra-abdominal Infections
Suwon, Gyeonggi-do, South Korea
View Trial DetailsNCT03830333
Complicated Intra-abdominal Infections
Hefei, Anhui, China
View Trial DetailsNCT01844856
Complicated Intra-abdominal Infections
Florence, Alabama, United States
View Trial DetailsNCT02784704
Complicated Appendicitis, Complicated Intra-abdominal Infections
Los Angeles, California, United States
View Trial Details